Expertise in
1
conditions

Dr. Anne F. Reilly

Hematology | Oncology
Childrens Health Care Associates Of NJ PC
1012 Laurel Oak Rd, 
Voorhees, NJ 
Expertise in
1
conditions
Childrens Health Care Associates Of NJ PC
1012 Laurel Oak Rd, 
Voorhees, NJ 

Overview

Anne Reilly is a Hematologist and an Oncologist practicing medicine in Voorhees, New Jersey.

Dr. Reilly is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Anaplastic Large Cell Lymphoma, Non-Hodgkin Lymphoma, and B-Cell Lymphoma.

She is actively involved in clinical research, co-authoring 49 peer reviewed articles and participating in 3 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in PA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Horizon Healthcare
  • EPO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Childrens Health Care Associates of NJ PC
1012 Laurel Oak Rd, Voorhees, NJ 08043
Other Locations
Children's Hospital of Philadelphia
3401 Civic Center Blvd, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Reilly has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Enrollment Status: Completed
Publish Date: January 26, 2026
Intervention Type: Biological
Study Drugs: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
Study Phase: Phase 2
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Enrollment Status: Completed
Publish Date: April 30, 2024
Intervention Type: Drug
Study Drugs: Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Study Phase: Phase 2
View 2 Less Clinical Trials

49 Total Publications

Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant.
Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant.
Journal: Pediatric blood & cancer
Published: July 01, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (13.6 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Janet Kwiatkowski is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Kwiatkowski is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Hemolytic Anemia, Congenital Hemolytic Anemia, Anemia, Bone Marrow Transplant, and Splenectomy.

Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Referral may be required

Office

3500 Civic Center Blvd, 
Philadelphia, PA 
 (13.5 miles away)
215-590-3025
Languages Spoken:
English

John Maris is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Maris is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Rhabdomyosarcoma.

Expertise in
26
conditions
Dr. Matthew J. Matasar
Hematology | Oncology
Expertise in
26
conditions
Dr. Matthew J. Matasar
Hematology | Oncology
Referral may be required

Rutgers Cancer Institute Of New Jersey

195 Little Albany St, 
New Brunswick, NJ 
 (52.9 miles away)
732-475-0824
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Matasar is a Hematologist and an Oncologist practicing medicine in New Brunswick, New Jersey. Dr. Matasar is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant. Dr. Matasar is currently accepting new patients.

Frequently Asked Questions about Dr. Anne F. Reilly

How do I make an appointment with Dr. Anne F. Reilly?

You can book an appointment with Dr. Anne F. Reilly by calling their office at 856-435-0086. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anne F. Reilly a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anne F. Reilly is classified as an Advanced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anne F. Reilly specialize in?

While Dr. Anne F. Reilly is a Hematology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Anaplastic Large Cell Lymphoma, and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Anne F. Reilly participate in research or clinical trials?

Yes. Dr. Anne F. Reilly has published 49 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Anne F. Reilly's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anne F. Reilly accept my insurance?

Dr. Anne F. Reilly accepts most major insurance plans, including Health Partners Plans and Horizon Healthcare. We recommend calling the office directly at 856-435-0086 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Reilly's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile